IP Library Granted Patent US 12,201,728
Granted Patent B2
US 12,201,728 · App. 17/673,429 · Granted Jan 21, 2025

Method of producing a microsphere comprising PLGA or PLA in which a biologically active substance is uniformly dispersed

Inventors: Masakazu Enomura (Izumi, JP); Kaeko Araki (Izumi, JP)
Assignee: M. TECHNIQUE CO., LTD.
A61K9/1647
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,201,728
App. No.
17/673,429
Granted
Jan 21, 2025
Kind
B2
Abstract

The present application provides a microsphere comprising a lactic acid-glycolic acid copolymer (PLGA) or polylactide (PLA) as a main component, in which a biologically active substance is uniformly dispersed, wherein an average volume-based particle diameter of the microsphere is 1 μm or more and 150 μm or less, and a variation coefficient of area ratios in six regions is 0.35 or less, wherein the area ratios in six regions are calculated by (s/A)×100 (%) wherein the six regions are prepared by preparing a cross section observation sample obtained by cutting the microsphere; observing the cross section observation sample with an electron microscope at a magnification capable of confirming the biologically active substance in the microsphere or a higher magnification; and dividing the electron microscope observation image into six regions; and A is an area of a respective divided region, and s is a sum of cross section areas of the biologically active substance included in the respective divided region. The microsphere of the present invention can appropriately control the initial release amount of the biologically active substance and its release rate during a subsequent release period, and can continuously release the biologically active substance in vivo for a predetermined period of time.

Claims (9)

1. A method of producing a microsphere comprising a lactic acid-glycolic acid copolymer (PLGA) or polylactide (PLA) as a main component, in which a biologically active substance is uniformly dispersed, comprising:

a step of continuously feeding to a pulverizing apparatus a solution of the PLGA or PLA and the biologically active substance obtained by dissolving or dispersing the PLGA or PLA and the biologically active substance in a good solvent of PLGA or PLA, and a solution containing a poor solvent of PLGA or PLA to prepare emulsified particles; and removing the good solvent from the prepared emulsified particles to precipitate the microsphere;

wherein the good solvent is a solvent which dissolves 0.1 g or more of PLGA or PLA in 100 g of the solvent at 25° C., and the poor solvent is a solvent which dissolves only 0.05 g or less of PLGA or PLA in 100 g of the solvent at 25° C.,

an average volume-based particle diameter of the microsphere is 1 μm or more and 150 μm or less, and

a variation coefficient of area ratios of an area of the biologically active substance to a cross-section area of the microsphere in six regions of the microsphere is 0.35 or less.

2. The method according to claim 1 , wherein the biologically active substance is a lipophilic biologically active substance.

3. The method according to claim 1 , wherein an average volume-based particle diameter of the dispersed biologically active substance is 5 nm to 500 nm.

4. The method according to claim 1 , wherein a content of the biologically active substance in the microsphere is 0.35 to 1.5% by mass.

5. The method according to claim 1 , wherein the good solvent is removed by blowing a gas on a surface of a fluid containing the emulsified particles, while stirring the fluid.

Priority Claims (1)
WO PCT/JP2020/018731 · May 8, 2020 · international
Continuity (2)
Division 17259690
Related Publication 20220168224A1 · Jun 2, 2022
References Cited (70)
US 5945126A · Thanoo et al. · 1999 [cited by applicant]
US 5945129A · Knerr et al. · 1999 [cited by applicant]
US 8222301B2 · Enomura · 2012 [cited by applicant]
US 9211510B2 · Enomura · 2015 [cited by applicant]
US 11285109B2 · Enomura · 2022 [cited by examiner]
US 11617720B2 · Enomura et al. · 2023 [cited by applicant]
US 20060134223A1 · Yamada · 2006 [cited by applicant]
US 20070059363A1 · Lee et al. · 2007 [cited by applicant]
US 20080102131A1 · Nagira et al. · 2008 [cited by applicant]
US 20090004283A1 · Petersen et al. · 2009 [cited by applicant]
US 20090011355A1 · Shibai · 2009 [cited by applicant]
US 20100155310A1 · Enomura · 2010 [cited by applicant]
US 20100203151A1 · Hiraoka · 2010 [cited by applicant]
US 20100272820A1 · Lim et al. · 2010 [cited by applicant]
US 20140341997A1 · Kim et al. · 2014 [cited by applicant]
US 20150321154A1 · Enomura · 2015 [cited by applicant]
US 20160089335A1 · Ohri et al. · 2016 [cited by applicant]
US 20170135960A1 · Yu et al. · 2017 [cited by applicant]
US 20170281547A1 · Karavas et al. · 2017 [cited by applicant]
CN 103054809A · 2013 [cited by applicant]
EP 0442671B1 · 1995 [cited by applicant]
JP 4114725A · 1992 [cited by applicant]
JP 2653255B2 · 1997 [cited by applicant]
JP 2001512461A · 2001 [cited by applicant]
JP 2002534392A · 2002 [cited by applicant]
JP 200515476A · 2005 [cited by applicant]
JP 200535994A · 2005 [cited by applicant]
JP 2009520727A · 2009 [cited by applicant]
JP 2009132871A · 2009 [cited by applicant]
JP 2010510206A · 2010 [cited by applicant]
JP 2010531303A · 2010 [cited by applicant]
JP 2011189348A · 2011 [cited by applicant]
JP 4856752B2 · 2012 [cited by applicant]
JP 5147091B1 · 2013 [cited by applicant]
JP 2014224114A · 2014 [cited by applicant]
JP 201669378A · 2016 [cited by applicant]
JP 2017509661A · 2017 [cited by applicant]
WO WO0040259A1 · 2000 [cited by applicant]
WO WO0110414A1 · 2001 [cited by applicant]
WO WO2008053920A1 · 2008 [cited by applicant]
WO WO2011112576A1 · 2011 [cited by applicant]
Lee et al., PLA Micro- and Nano-Particles, Adv Drug Delivery Rev, 15; 107; 178-191 (Year: 2016). [cited by examiner]
Extended European Search Report dated Nov. 2, 2023 for Application No. 20934454.8. [cited by applicant]
Jordan et al., “Comparative Study of Chemoembolization Loadable Beads: In vitro Drug Release and Physical Properties of DC Bead and Hepasphere Loaded with Doxorubicin and Irinotecan”, J Vasc Interv Radiol, vol. 21, No. … [cited by applicant]
International Search Report (PCT/ISA/210) issued in PCT/JP2020/034524 mailed on Oct. 27, 2020, with translation. [cited by applicant]
Lee et al., PLA Micro and Nano-Particles, Adv Drug Delivery Rev, 15; 107: 176-191 (Year: 2016). [cited by applicant]
Written Opinion (PCT/ISA/237) issued in PCT/JP2020/034524 mailed on Oct. 27, 2020, with translation. [cited by applicant]
U.S. Appl. No. 18/349,753, filed Jul. 10, 2023. [cited by applicant]
U.S. Appl. No. 18/112,747, filed Feb. 22, 2023. [cited by applicant]
Kiss et al., “The Influence of Process Parameters on the Properties of PLGA-Microparticles Produced by the Emulsion Extraction Method,” AlChE Journal, vol. 59, No. 6, 2013 (published online Dec. 20, 2012), pp. 1868-1881. [cited by applicant]
U.S. Office Action for U.S. Appl. No. 18/349,753, dated Apr. 17, 2024. [cited by applicant]
Zhao et al., “Hierarchically porous composite microparticles from microfluidics for controllable drug delivery,” Nanoscale, vol. 10, 2018, pp. 12595-12604. [cited by applicant]
Busatto et al., “Effect of Particle Size, Polydispersity and Polymer Degradation on Progesterone Release from PLGA Microparticles: Experimental and Mathematical Modeling”, International Journal of Pharmaceutics, vol. 53… [cited by applicant]
Chinese Office Action and Search Report dated May 25, 2023 for Application No. 202080100595.1 with an English translation. [cited by applicant]
Chinese Office Action and Search Report for Chinese Application No. 202080025520.1, dated Aug. 12, 2022, with an English translation of the Chinese Office Action. [cited by applicant]
Dong et al., “Development of composite PLGA microspheres containing exenatide-encapsulated lecithin nanoparticles for sustained drug release”, 2020, Elsevier, Asian Journal of Pharmaceutical Sciences, vol. 15, pp. 347-3… [cited by applicant]
Extended European Search Report for European Application No. 20934379.7, dated Mar. 23, 2023. [cited by applicant]
International Search Report, issued in PCT/JP2020/044366, dated Jan. 12, 2021, with English translation. [cited by applicant]
Kikuchi, Drug Delivery System, 2014, vol. 29, No. 1, pp. 51-63. [cited by applicant]
Product information for “PC-98T Egg yolk lecithin I 93685-90-6”, retrieved from: <http://en.avt-avt.com/product-item-79.html> on Jul. 28, 2022, pp. 1-2. [cited by applicant]
Soppimath et al., “Biodegradable polymeric nanoparticles as drug delivery devices”, 2001, Elsevier, Journal of Controlled Release, vol. 70, pp. 1-20. [cited by applicant]
The Merck Index Online (TM) entry for “Latanoprost” (M6701), p. 1, 2013. [cited by applicant]
The Merck Index Online entries for Camptothecin (M3007), Cyclosporines (M4020), Ibuprofen (M6189), Indomethacin (M6279), Tacrolimus (M 10425), Tranilast (M11001), and Triamcinolone (M11027), pp. 1-14, 2013. [cited by applicant]
Wang et al., “Enhanced encapsulation and bioavailability of breviscapine in PLGA microparticles by nanocrystal and water-soluble polymer template techniques”, 2017, Elsevier, European Journal of Pharmaceutics and Biopha… [cited by applicant]
Written Opinion of the International Searching Authority, issued in PCT/JP2020/044366, dated Jan. 12, 2021, with English translation. [cited by applicant]
Xie et al., “Progesterone PLGA/mPEG-PLGA Hybrid Nanoparticle Sustained-Release System by Intramuscular Injection”, 2018, Springer, Pharmaceutical Research, vol. 35, No. 62, pp. 1-10. [cited by applicant]
Allison, “Analysis of initial burst in PLGA microparticles,” Expert Opinion on Drug Delivery, vol. 5, No. 6, 2008, pp. 615-628. [cited by applicant]
U.S. Office Action for U.S. Appl. No. 18/349,753, dated Jul. 18, 2024. [cited by applicant]
Hewlings et al., “Curcumin: A Review of Its' Effects on Human Health,” Foods, vol. 6, No. 92, 2017, pp. 1-11. [cited by applicant]
U.S. Office Action for U.S. Appl. No. 18/112,747, dated May 23, 2024. [cited by applicant]